Article

New form of brachytherapy shows promise

An experimental form of brachytherapy was highly efficacious and minimally toxic to healthy tissue in a mouse model of cancer, according to a recent study.

Related Videos
1 expert is featured in this series.
Targeted Therapy in mHSPC: Effects of Mutation Absence
Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC
Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC
An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC
An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC
1 expert is featured in this series.
Treatment Strategies for Symptomatic Bone Metastases in mHSPC
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jared S. Winoker, MD, answers a question during a Zoom video interview
Jared S. Winoker, MD, discusses real-world study of CVAC 2.0 for kidney stones
Jim Hu, MD, on urinary continence recovery across RARP techniques
Jim Hu, MD, on urinary continence recovery across RARP techniques
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
1 expert in this video
Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
1 expert in this video
Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
Related Content
Intraprostatic drug elution therapy shows promise for BPH-related LUTS
May 29th 2025

Intraprostatic drug elution therapy shows promise for BPH-related LUTS

Hannah Clarke
Further follow-up and additional treatments in the study are ongoing.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Phase 3 trial of tebipenem HBr for cUTI stopped early for efficacy
May 28th 2025

Phase 3 trial of tebipenem HBr for cUTI stopped early for efficacy

Hannah Clarke
These data are intended to support a new drug application to the FDA in the second half of 2025.
Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
May 4th 2025

Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
Combination therapy linked to longer OS vs ADT in veterans with mHSPC
May 27th 2025

Combination therapy linked to longer OS vs ADT in veterans with mHSPC

Hannah Clarke
However, the data did not show any benefit of a docetaxel doublet vs an ARPI doublet.
Kidney stones | Image Credit: © airborne77 - stock.adobe.com
May 26th 2025

Clarifying CPT 52353 billing for same-side stone cases

Jonathan Rubenstein, MD Mark Painter
Jonathan Rubenstein, MD, and Mark Painter tackle a coding question for treating stones.
© 2025 MJH Life Sciences

All rights reserved.